Aprea Therapeutics (APRE) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 5, 2025, with stockholders able to vote online, by phone, or by mail.

• Four main proposals are up for vote: election of three directors, ratification of the auditor, advisory vote on executive compensation, and advisory vote on the frequency of future say-on-pay votes.

• The board recommends voting in favor of all proposals and supports annual say-on-pay votes.

Voting matters and shareholder proposals

• Stockholders will vote to elect three Class III directors for three-year terms expiring in 2028.

• Ratification of EisnerAmper LLP as the independent registered public accounting firm for 2025 is proposed.

• Advisory votes on executive compensation and the frequency of future say-on-pay votes are included, with the board recommending annual votes.

• No other matters are expected to be presented for a vote.

Board of directors and corporate governance

• The board consists of nine members divided into three classes with staggered three-year terms.

• Eight out of nine directors are independent; the CEO is not independent.

• The board has separate CEO and Chairman roles, with Dr. Peters as Chairman and Dr. Gilad as CEO.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Research and Development, all composed of independent directors.

• The board values diversity, regular self-evaluation, and stockholder engagement.